Dogwood Therapeutics (DWTX) investor relations material

Corporate overview and leadership

• Headquarters in Atlanta, GA, listed on Nasdaq under DWTX, with 33.6M shares outstanding and $13.2M cash as of March 31, 2026.

• Analyst coverage by H.C. Wainwright and Maxim Group.

• Leadership team with proven drug development and commercial success, including experience with major pharmaceuticals like Zoloft, Viagra, Lipitor, and Lyrica.

• Recent pipeline acquisitions and licensing: Halneuron® (Q4 2024), SP16 (Q4 2025), and out-licensing of IMC-1/IMC-2 (Q2 2026).

Therapeutic pipeline and clinical progress

• Halneuron® (Tetrodotoxin) targets chemotherapy-induced neuropathic pain (CINP) and general cancer pain, with Fast Track designation.

• SP16, a peptide therapy, is advancing for acute surgical pain and chemotherapy-induced peripheral neuropathy (CIPPN), with NCI-funded studies.

• Halneuron® demonstrated statistically significant and durable pain reduction in Phase 2 studies, with a favorable safety profile.

• Phase 2b CINP study interim analysis shows efficacy, durable response, and low drop-out rates compared to existing treatments.

• Key 2026 milestones include FDA submissions, Phase 2b completion, and Phase 1b enrollment for SP16.

Market opportunity and unmet need

• Over 3 million US patients suffer from CINP, with 7.5 million experiencing painful neuropathy.

• CINP treatment market across US, UK, EU4, and Japan is valued at $1B, projected to reach $3B by 2036.

• No FDA-approved treatments for CINP; current therapies include SNRIs, opioids, and tricyclic antidepressants.

• Halneuron® targets an initial approval for ~4 million moderate-to-severe CINP patients by 2030.

• Expansion potential into the broader $7.5B cancer-related pain market.